Liminatus Pharma (LIMN) Competitors $3.02 -0.23 (-7.08%) As of 08/27/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock LIMN vs. BNTC, ALDX, AMRN, CAPR, CTMX, ALT, FDMT, TNXP, LRMR, and DMACShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include Benitec Biopharma (BNTC), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Capricor Therapeutics (CAPR), CytomX Therapeutics (CTMX), Altimmune (ALT), 4D Molecular Therapeutics (FDMT), Tonix Pharmaceuticals (TNXP), Larimar Therapeutics (LRMR), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors Benitec Biopharma Aldeyra Therapeutics Amarin Capricor Therapeutics CytomX Therapeutics Altimmune 4D Molecular Therapeutics Tonix Pharmaceuticals Larimar Therapeutics DiaMedica Therapeutics Liminatus Pharma (NASDAQ:LIMN) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings. Do insiders & institutionals hold more shares of LIMN or BNTC? 52.2% of Benitec Biopharma shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor LIMN or BNTC? In the previous week, Benitec Biopharma had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 2 mentions for Benitec Biopharma and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.88 beat Benitec Biopharma's score of 1.28 indicating that Liminatus Pharma is being referred to more favorably in the media. Company Overall Sentiment Liminatus Pharma Very Positive Benitec Biopharma Positive Do analysts rate LIMN or BNTC? Benitec Biopharma has a consensus price target of $26.00, indicating a potential upside of 102.18%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is LIMN or BNTC more profitable? Liminatus Pharma's return on equity of 0.00% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Liminatus PharmaN/A N/A N/A Benitec Biopharma N/A -38.26%-35.71% Which has better earnings and valuation, LIMN or BNTC? Liminatus Pharma has higher earnings, but lower revenue than Benitec Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLiminatus PharmaN/AN/AN/AN/AN/ABenitec Biopharma$80K4,219.69-$21.75M-$1.51-8.52 SummaryBenitec Biopharma beats Liminatus Pharma on 8 of the 11 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$84.55M$200.47M$2.55B$9.78BDividend YieldN/AN/A2.54%4.02%P/E RatioN/AN/A21.8126.37Price / SalesN/AN/A89.36121.31Price / CashN/AN/A23.3859.36Price / BookN/AN/A33.916.62Net IncomeN/AN/A$26.72M$265.42M7 Day Performance8.63%-2.35%2.10%3.08%1 Month Performance-62.62%-32.44%1.93%0.77%1 Year PerformanceN/A132.56%32.46%22.97% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$3.02-7.1%N/AN/A$84.55MN/A0.00N/ANews CoveragePositive NewsBNTCBenitec Biopharma1.55 of 5 stars$12.88+2.5%$26.00+101.9%+37.4%$338.10M$80K-8.5320ALDXAldeyra Therapeutics1.7318 of 5 stars$5.63+0.5%$9.50+68.7%+8.9%$337.24MN/A-6.6210AMRNAmarin0.2661 of 5 stars$15.85+0.2%$12.00-24.3%+24.6%$328.21M$219.36M-4.32360Analyst DowngradeCAPRCapricor Therapeutics3.051 of 5 stars$7.17-6.5%$22.56+214.6%+30.6%$327.81M$22.27M-4.37101Gap DownCTMXCytomX Therapeutics4.3831 of 5 stars$1.97-1.5%$5.75+191.9%+73.9%$324.87M$138.10M3.52170Positive NewsALTAltimmune3.3375 of 5 stars$3.63+0.3%$17.40+379.3%-45.2%$320.37M$20K-3.0850Trending NewsFDMT4D Molecular Therapeutics2.2764 of 5 stars$6.85+4.3%$30.40+343.8%-58.4%$319.91M$33K-1.94120TNXPTonix Pharmaceuticals3.1649 of 5 stars$36.05-1.3%$70.00+94.2%-11.4%$316.16M$10.09M-0.9150LRMRLarimar Therapeutics2.4164 of 5 stars$3.77+3.3%$18.43+388.8%-51.6%$312.07MN/A-2.4230Positive NewsDMACDiaMedica Therapeutics1.4779 of 5 stars$6.00+4.0%$12.33+105.6%+51.4%$310.14MN/A-8.7020Analyst Upgrade Related Companies and Tools Related Companies Benitec Biopharma Competitors Aldeyra Therapeutics Competitors Amarin Competitors Capricor Therapeutics Competitors CytomX Therapeutics Competitors Altimmune Competitors 4D Molecular Therapeutics Competitors Tonix Pharmaceuticals Competitors Larimar Therapeutics Competitors DiaMedica Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access